Chromadex, Inc. v. Elysium Health, Inc.
301 F. Supp. 3d 963
C.D. Cal.2017Background
- ChromaDex (plaintiff) supplied Elysium (defendant) with two proprietary ingredients (NIAGEN®/NR and pTeroPure®) under supply and trademark/royalty agreements executed in 2014.
- In mid-2016 Elysium placed unusually large discounted purchase orders, accepted discounted pricing, then refused to pay invoices totaling about $3M, allegedly citing unresolved contract concerns.
- ChromaDex alleges Elysium induced large shipments by false promises of "ramping up" and later conspired with two former ChromaDex employees who joined Elysium to obtain confidential partner/customer information.
- ChromaDex sued for breach of the supply and royalty agreements, fraudulent deceit, and trade-secret misappropriation (state and federal). Elysium counterclaimed for breach, fraudulent inducement, patent misuse (tying trademark-license royalties to NR supply), and UCL violations.
- The court considered motions to dismiss: it dismissed ChromaDex's fraud claim with prejudice (economic-loss rule), dismissed trade-secret claims with leave to amend (insufficient specificity about secrecy/value), sustained Elysium's fraudulent-inducement and patent-misuse counterclaims, and dismissed Elysium's UCL claim without leave to amend.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether ChromaDex's fraudulent-deceit claim survives given contract damages (economic-loss rule) | ChromaDex: statements induced performance beyond contractual expectations; exception for intentional misrepresentation | Elysium: injury is purely economic from contract breach; fraud claim is repackaged contract claim | Dismissed with prejudice — economic-loss rule applies; Robinson Helicopter exception not met |
| Whether ChromaDex adequately alleged trade-secret misappropriation (CUTSA/DTSA) | ChromaDex: alleged confidential partner/customer lists, clinical data, and internal efforts to maintain secrecy | Elysium: allegations are conclusory; customer identities/contacts are readily ascertainable and lack showing of independent economic value | Dismissed with leave to amend — insufficient factual detail under Morlife standard |
| Whether Elysium plausibly alleged fraudulent inducement of the License & Royalty Agreement | Elysium: CEO represented all NR purchasers had to sign royalty/license agreements; that induced Elysium to stop negotiating royalties | ChromaDex: fails Rule 9(b), spreadsheet evidence post-dates the alleged misstatement; reliance implausible given protracted negotiations | Counterclaim survives — allegations (spreadsheet, email, conduct) sufficiently plead falsity, knowledge, and reliance |
| Whether Elysium stated a claim for patent misuse (tying royalties/license to NR supply) | Elysium: ChromaDex conditioned supply of NR on purchasing trademark license and paying royalties, unlawfully extending patent power | ChromaDex: royalty/license optional and not a separate tied product; misuse is only an equitable defense to infringement | Counterclaim survives — declaratory relief proper under MedImmune; tying sufficient because trademark license is separate from NR supply (Senza-Gel/ZENITH principles) |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading legal conclusions not entitled to presumption of truth)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (complaint must state plausible claim)
- Robinson Helicopter Co. v. Dana Corp., 34 Cal.4th 979 (economic-loss rule and narrow fraud exception)
- Morlife, Inc. v. Perry, 56 Cal.App.4th 1514 (limits on trade-secret protection for readily ascertainable customer lists)
- MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (declaratory-judgment jurisdiction requires case-or-controversy)
- Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100 (patent-license royalty demands can constitute misuse)
- Eastman Kodak Co. v. Image Technical Services, Inc., 504 U.S. 451 (definition of tying arrangement)
- Senza-Gel Corp. v. Seiffhart, 803 F.2d 661 (product separability in patent-misuse analysis)
- Linear Technology Corp. v. Applied Materials, Inc., 152 Cal.App.4th 115 (limits on UCL suits between commercial parties)